>細(xì)胞CELL>ATCC普通細(xì)胞>Panc 10.05
ATCC Number:CRL-2547?
運(yùn)輸方式:凍存運(yùn)輸
器官來源:胰腺
相關(guān)疾?。合侔?br />
細(xì)胞形態(tài):上皮樣
年限:adult
是否是腫瘤細(xì)胞:0
物種來源:人
數(shù)量:大量
生長狀態(tài):貼壁生長
規(guī)格:0.2ml Designations: Panc 10.05
Depositors: ?EM Jaffee
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens deposited as human
Morphology:epithelial
Source: Organ: pancreas
Disease: adenocarcinoma
Cellular Products:cytokeratins 7 and 18 [50655 ]
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: 1992
Tumorigenic:Yes
Oncogene:K-ras +
Antigen Expression:MHC class I +; MHC class II -
DNA Profile (STR):Amelogenin: X
CSF1PO: 12
D13S317: 12
D16S539: 9,12
D5S818: 13
D7S820: 8,9
THO1: 6,9.3
TPOX: 11
vWA: 16
Age: adult
Gender: male
Ethnicity: White
Comments:Panc 10.05 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma.
Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655 ]
The cells have a reported plating efficiency of 40%. [50655 ]
The Panc 10.05 cell line was derived from the same patient as the PL45 cell line (ATCC CRL-2558 ).
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 10 Units/ml human insulin, 85%; fetal bovine serum, 15%
Temperature: 37.0°C
Subculturing: Protocol:
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 19.2 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
derived from same individual:ATCC CRL-2558
References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602